A Study of BL-M07D1 in Patients With HER2-mutated, Locally Advanced or Metastatic Non-small-cell Lung Cancer

This study tests a new drug called BL-M07D1 in patients with non-small cell lung cancer (NSCLC) that carries a HER2 mutation — a specific genetic change that affects how cancer cells grow. HER2-mutated lung cancer is hard to treat with standard therapies. **You may be eligible if:** - You are between 18 and 75 years old - You have confirmed advanced or metastatic non-small cell lung cancer that cannot be surgically removed - Your tumor has a known HER2-sensitizing mutation - You have received at least one prior line of treatment - Your expected survival is at least 3 months - Your organ function (heart, liver, kidneys) is adequate **You may NOT be eligible if:** - Your cancer does not have a HER2 mutation - You have received a prior anti-HER2 drug that is in the same class as BL-M07D1 - You have active brain metastases or other serious conditions - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.